Key result
Amiodarone produces QT lengthening to 500 to 700 msec with a negligibly low incidence of torsades de pointes, and ranolazine shares similar properties that may prevent drug-induced arrhythmias.
Design
Review
Authors
Loading...
Supports niche role for amiodarone/ranolazine against class III-induced torsades; leaves open confirmation in prospective trials.
Amiodarone and ranolazine may have a therapeutic niche in preventing drug-induced torsades de pointes associated with pure class III antiarrhythmic agents.
Singh et al. (2004) conducted a review in Cardiac arrhythmias. Amiodarone and Ranolazine was evaluated. Amiodarone produces QT lengthening to 500 to 700 msec with a negligibly low incidence of torsades de pointes, and ranolazine shares similar properties that may prevent drug-induced arrhythmias.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: